戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1 line, 2) after 4 weeks of CSII, and 3) after CSII plus either troglitazone or metformin.
2 bject, paired comparison of MDI and CSII and CSII with 12 months postislet transplantation in 10 type
3 within-subject, paired comparison of MDI and CSII and CSII with 12 months postislet transplantation i
4  accessibility of and reimbursement for CGM, CSII, glucometers, and insulin.
5           However, the longevity of clinical CSII is limited by skin complications, by impaired insul
6 s used randomized crossover design comparing CSII versus CLC during identical 22-h hospitalizations i
7 I group who completed the trial discontinued CSII.
8 on glycemic control and hypoglycemia, except CSII has a favorable effect on glycemic control in adult
9          Centers with full reimbursement for CSII, CGM, glucometers, and insulin showed mean HbA1c le
10 ng automated data transfer CGM-->algorithm-->CSII.
11 ing effects than metformin (1,700 mg/day) in CSII-treated euglycemic patients.
12 ), continuous subcutaneous insulin infusion (CSII) and islet transplantation to reduce hypoglycemia a
13 of continuous subcutaneous insulin infusion (CSII) before randomization to CSII plus troglitazone (n
14    Continuous subcutaneous insulin infusion (CSII) is an essential insulin replacement therapy in the
15 p (continuous subcutaneous insulin infusion [CSII]), known as artificial pancreas, can help optimize
16 y (continuous subcutaneous insulin infusion; CSII) in patients with type 1 diabetes using continuous
17 .9-10.0 mmol/L) is improved by initiation of CSII in adults with type 1 diabetes.
18 ssociated with the subcutaneous insertion of CSII catheters, which require replacement and rotation o
19 ic clamp 1) at baseline, 2) after 4 weeks of CSII, and 3) after CSII plus either troglitazone or metf
20  agents despite lower insulin levels than on CSII alone.
21 zation to CSII plus troglitazone (n = 10) or CSII plus metformin (n = 10); euglycemia was maintained
22  0.9; 3.3 mmol/mol [SD 9.8]) in the CGM plus CSII group and 0.1% (0.4; 1.1 mmol/mol [4.4]) in the CGM
23  36 (97%) of 37 participants in the CGM plus CSII group and 35 (92%) of 38 participants in the CGM pl
24 pants were randomly assigned to the CGM plus CSII group and 38 participants were randomly assigned to
25 s 6.7 days per week (SD 0.8) in the CGM plus CSII group and 6.9 days per week (0.3) in the CGM plus M
26 was 791 min per day (SD 157) in the CGM plus CSII group and 741 min per day (225) in the CGM plus MDI
27                 Participants in the CGM plus CSII group had a greater reduction in CGM-measured mean
28              No participants in the CGM plus CSII group who completed the trial discontinued CSII.
29 rred in one participant each in the CGM plus CSII group.
30 ubcutaneous insulin infusion (insulin pumps [CSII]), and glucometers alongside insulin access represe
31 ring the tip end of commercial off-the-shelf CSII catheters fully resolves early skin irritations, ex
32  minipigs (from 2 to 13 days, under standard CSII-wearing conditions of insulin pump therapy and in a
33 I alone) and was then 45% higher than in the CSII plus metformin patients (P < 0.005).
34 to it, and should be generally applicable to CSII catheters and other implantable devices.
35                   After changing from MDI to CSII before transplantation, 10 subjects reduced median
36 hing from multiple daily injections (MDI) to CSII in adults with type 1 diabetes using CGM.
37 ulin infusion (CSII) before randomization to CSII plus troglitazone (n = 10) or CSII plus metformin (
38 erated sequence to continue MDI or switch to CSII, with continuation of CGM, for 28 weeks.
39 glycemia suitable for islet transplantation, CSII decreased hypoglycemia frequency and glycemic varia
40 reductions in all baseline parameters versus CSII, respectively, HbA1c (6.4% cf 8.2%), median HYPOsco
41 % with CSII plus troglitazone (P < 0.005 vs. CSII alone) and was then 45% higher than in the CSII plu
42 h CSII plus metformin, but improved 29% with CSII plus troglitazone (P < 0.005 vs. CSII alone) and wa
43      Good glycemic control was achieved with CSII alone and was maintained with CSII plus an oral age
44 ecreased 53% with troglitazone compared with CSII alone (48+/-4 vs. 102+/-13 U/day, P < 0.001), but o
45 eved with CSII alone and was maintained with CSII plus an oral agent (mean 24-h glucose: troglitazone
46 s mellitus, HbA1c levels decreased more with CSII than with MDI, but 1 study heavily influenced these
47 change significantly with CSII alone or with CSII plus metformin, but improved 29% with CSII plus tro
48 ensitivity did not change significantly with CSII alone or with CSII plus metformin, but improved 29%
49 time hypoglycemic on CGM were unchanged with CSII, SD glucose and CONGA4 reduced significantly (P < 0